Does CETUXIMAB Cause Malignant neoplasm progression? 662 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 662 reports of Malignant neoplasm progression have been filed in association with CETUXIMAB (ERBITUX). This represents 4.6% of all adverse event reports for CETUXIMAB.
662
Reports of Malignant neoplasm progression with CETUXIMAB
4.6%
of all CETUXIMAB reports
225
Deaths
172
Hospitalizations
How Dangerous Is Malignant neoplasm progression From CETUXIMAB?
Of the 662 reports, 225 (34.0%) resulted in death, 172 (26.0%) required hospitalization, and 27 (4.1%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CETUXIMAB. However, 662 reports have been filed with the FAERS database.
What Other Side Effects Does CETUXIMAB Cause?
Off label use (1,549)
Rash (883)
Diarrhoea (874)
Neutropenia (744)
Nausea (663)
Dyspnoea (542)
Decreased appetite (541)
Vomiting (533)
Death (518)
Anaemia (508)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which CETUXIMAB Alternatives Have Lower Malignant neoplasm progression Risk?
CETUXIMAB vs CETYLPYRIDINIUM
CETUXIMAB vs CEVIMELINE
CETUXIMAB vs CHAMPIX
CETUXIMAB vs CHANTIX
CETUXIMAB vs CHENODIOL